Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorNadezhda Women's Health Hospital
About this trial
The goal of this clinical trial is to test the effect of modulated specialised immune cells isolated from the patients' own blood when administered to the uterus before embryo transfer on the IVF outcome (implantation, pregnancy and live birth rates).
To achieve this, blood will be obtained from eligible participants. Target cells will be isolated and incubated with the tested modulator for 24h, and returned to the uterine cavity 1 day prior to embryo transfer.
Researchers will compare the reproductive outcome of the tested intervention to that of a control group who will not receive the investigated cell treatment prior to embryo transfer.
Eligibility criteria
Qualifiers
Participating in Assisted Reproduction Treatment
Having primary infertility
Having regular menstrual cycles
Scheduled to undergo embryo transfer of euploid embryos only
Disqualifiers
Uterine pathologies
Endometrial bacterial infections
Active endometrial inflammation
Polycystic ovary syndrome
Trial design
Treatments tested in this trial
- PBMC immunomodulated with IFNt
Treatment groups
300 Participants
are divided into 2 treatment groupsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Nadezhda Women's Health HospitalRecruiting1330, Sofia, Sofia
Bulgaria
BulgariaSponsors and collaborators
Source ClinicalTrials.gov